Corridor · Sourcing Intelligence
Akunudo screens manufacturers of Ibuprofen 400mg for Egypt registration before you ever see them — certification, stability zone for the climate, and dossier format clear first; commercial fit second. Identities stay sealed until NDA, so you can source without tipping your hand.
No manufacturer in the corridor matches this exact spec for Egypt right now.
Submit a mandate and we'll match it the moment a qualified manufacturer enters the corridor — and alert you.
Not a directory to wade through — a brokered, anonymized corridor. We only fully win when your deal closes.
Market access · Egypt
The Egyptian Drug Authority (Law 151/2019) is the single regulator; registration uses CTD, needs a local importer/representative, and offers strong reliance routes recognising EU/US-FDA/WHO-PQ approvals. Egypt is a hard pricing market — prices are state-set by external reference pricing pegged to the lowest in a large basket minus 10% — with reimbursement shifting to a phased Universal Health Insurance rollout while out-of-pocket spending stays high (~60%) and centralised UPA tenders dominate public access.
The Egyptian Drug Authority (EDA, Law 151/2019): applications run through EDA's electronic system, scientific committees evaluate the dossier and the Technical Committee for Drug Control issues the marketing-authorisation decision.
CTD (adopted via EDA Chairman Decree 343/2021). Confirm whether full eCTD electronic publishing is required for your specific track.
A foreign company can be the marketing-authorisation holder, but with no Egyptian presence it must operate through an EDA-licensed local scientific office and/or importer to file and maintain the registration and to import.
Yes. EDA's Reliance Practices provide a Verification route (approved by two stringent authorities, or one plus WHO-PQ) and an Abridged route (one SRA or WHO-PQ), recognising ~24 reference authorities including US-FDA and EMA, with priority for innovator/unmet-need/shortage products and a separate emergency-use pathway.
A valid GMP certificate and a WHO-format CPP are required; EDA waives the on-site inspection for products from reference countries (reviewing the certificate only) and inspects the overseas site only where GMP evidence is lacking.
Orientation intelligence compiled from public regulator and analyst sources as of the dates shown — not legal or regulatory advice. Rules change; confirm specifics (fees, timelines, baskets, eligibility) with the authority before acting. (Authority: EDA — Egyptian Drug Authority; as of 2026-06.)